Contact | Print version | PDF version | Send article | RSS feed

OncoMethylome Sciences to Perform MGMT Testing in Roche Phase III Study of Avastin for Glioblastoma

OncoMethylome's Technology is being used in Roche Clinical Trial Program with Avastin

07 Jan 2010 - OncoMethylome Sciences announced that it has entered into an agreement with F. Hoffmann-La Roche Ltd., of Basel Switzerland, for MGMT gene promoter methylation testing in a Phase III clinical trial for the use of Avastin in newly diagnosed (glioblastoma [GBM]) brain tumors.
 
This trial will compare the current standard-of-care therapy, which is concurrent chemoradiation and adjuvant temozolomide "TMZ" (Temodar, Schering-Plough), with the standard-of-care plus bevacizumab (Avastin, Roche). All patients will be randomized to TMZ and radiotherapy or TMZ, radiotherapy and bevacizumab. OncoMethylome Sciences will receive payments for performing MGMT testing, using their patented Methylation-Specific PCR (MSP) technology, on all patients enrolled in this trial.
 
Mr. Luc Segers, Senior Director Business Development at OncoMethylome commented, "We are very pleased that MGMT testing will be incorporated into this study, once again demonstrating the market interest in identifying biomarkers that will lead to more personalized healthcare."